$21.8 billion drug maker, Eli Lilly and Co., said it plans to create four new senior-level ethics and compliance positions to further support the centralized global compliance and enterprise risk management function, the company said in a filing. The establishment of the new positions are part of a deal to settle two shareholder lawsuits over the improper marketing of numerous of its drugs.

Learn More
Already a member? Sign in to an existing account.

Jaclyn Jaeger is a freelance contributor to Compliance Week after working for the company for 15 years. She writes on a wide variety of topics, including ethics and compliance, risk management, legal,...